Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Liabilities (2017 - 2025)

Dr Reddys Laboratories (RDY) has 7 years of Total Liabilities data on record, last reported at $1.3 billion in Q1 2024.

  • For Q1 2024, Total Liabilities rose 16.53% year-over-year to $1.3 billion; the TTM value through Mar 2024 reached $1.3 billion, up 16.53%, while the annual FY2024 figure was $1.3 billion, 14.09% up from the prior year.
  • Total Liabilities reached $1.3 billion in Q1 2024 per RDY's latest filing, up from $1.1 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.4 billion in Q1 2022 and bottomed at $1.1 billion in Q1 2020.
  • Average Total Liabilities over 5 years is $1.2 billion, with a median of $1.3 billion recorded in 2021.
  • Peak YoY movement for Total Liabilities: increased 18.88% in 2021, then dropped 18.75% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $1.1 billion in 2020, then rose by 18.88% to $1.3 billion in 2021, then rose by 7.32% to $1.4 billion in 2022, then dropped by 18.75% to $1.1 billion in 2023, then increased by 16.53% to $1.3 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $1.3 billion in Q1 2024, $1.1 billion in Q1 2023, and $1.4 billion in Q1 2022.